Search
Selected Filter
Displaying 231–240 of 541 news results
-
Foundation News
This June 30th exclusive conversation and acoustic performance by Grammy-nominated rocker Grace Potter will raise awareness and funds to find treatments and cures for blinding diseases.
-
Biogen’s Phase 3 Clinical Trial for its Choroideremia Gene Therapy Doesn’t Meet Endpoints
Research NewsAdditional results from the trial will be reported at a future scientific meeting
-
Two Blind Brothers Hosts Foundation Fighting Blindness Virtual Gala "Night for Sight"
Foundation NewsThis virtual event on June 24, featuring entertainment from Sheryl Crow, will raise awareness and funds to find treatments and cures for blinding diseases.
-
Foundation Fighting Blindness to Host National Virtual VisionWalk
Foundation NewsThe Spring Virtual VisionWalk on June 12th will raise awareness and fund research finding treatments and cures for blinding retinal diseases.
-
Investigators Report Partial Vision Restoration for One Patient in Optogenetic Therapy Trial
Research NewsThe gene-agnostic approach is designed to restore some vision to people with advanced vision loss
-
New Bipartisan Legislation Introduced to Boost Clinical Research for Treatments and Cures
Research NewsThe bill would provide loans to therapy developers ready to launch clinical trials for a broad range of conditions including eye diseases.
-
Foundation Fighting Blindness Applauds Introduction of LOANS for Biomedical Research Act
Foundation NewsLegislation provides innovative financing for clinical trials stalled by COVID-19 pandemic.
-
Foundation News
The free webinar for eye care professionals, on June 21, will feature some of the intriguing and innovative research efforts underway for inherited retinal diseases and AMD.
An overview of the Foundation’s no-cost genetic testing program will also be presented.
-
In the Press
Uses novel, mutation agnostic optogenetics approach to restore vision in underserved forms of blindness. Company backed by leading life science investors including Octagon Capital, Samsara BioCapital and Casdin Capital, along with founding investors Atlas Venture, Mission BioCapital and Foundation Fighting Blindness.
-
Biogen’s Phase 2/3 Clinical Trial for XLRP Gene Therapy Doesn’t Meet Primary Endpoint
Research NewsMore details from the clinical trial will be reported at a later date
